
Opinion|Videos|January 24, 2025
Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg
Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Aflibercept 8 mg was evaluated in the PULSAR and PHOTON trials for neovascular age-related macular degeneration and diabetic macular edema. Could you briefly review the design of these trials?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
2
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
3
NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101
4
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
5



































